ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION

• Main Authors: M. V. Leonova, M. A. Demidova, A. V. Tarasov, Y. V. Belousov
• Format: Article
• Language: English
• Published: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
• Series: Racionalʹnaâ Farmakoterapiâ v Kardiologii
• Subjects: артериальная гипертензия; спираприл; эндотелиальная функция; нефропротекция; липиды; метаболизм глюкозы
• Online Access: http://www.rpcardio.ru/jour/article/view/346
• ISSN: 1819-6446; 2225-3653

<p><strong>Aim.</strong> To estimate antihypertensive, organ protective and metabolic efficiency of angiotensin converting enzyme (ACE) inhibitor spirapril in patients with arterial hypertension (AH).</p><p><strong>Material and methods.</strong> 30 patients with AH of I-II grade with different cardiovascular risk were included into the study. Spirapril was prescribed in the dose of 3 mg once daily. If necessary, daily dose could be increased to 6 mg after two weeks, and after next 4 weeks hydrochlorothiazide in daily dose 12,5-25 mg could be added. Treatment lasted 16 weeks. Before and after 16-week treatment ambulatory blood pressure monitoring (ABPM) was carried out. At the same time vasodilatation tests for reactive hyperemia and nitroglycerin were held, microalbuminuria and β2-microglobulinuria levels were defined, figures of lipid and glucose metabolism were studied, questionnaires for quality of life were filled in.</p><p><strong>Results.</strong> 27 patients with AH finished the study according to protocol. Treatment with spirapril within 16 weeks caused normalization of blood pressure in 60% of patients, decreased levels of microalbuminuria (p&lt;0,05) and β2-microglobulinuria (p&lt;0,05), recovered significantly disrupted endothelial function according to the results of vasodilatation tests (p&lt;0,01), improved patients quality of life (p&lt;0,05). Spirapril didn’t change lipid and glucose metabolism, regardless that in 1/3 of cases it was used in combination with hydrochlorothiazide.</p><p><strong>Conclusion.</strong> Spirapril is a highly efficient antihypertensive drug with organ protective effect and metabolic neutrality. According to the revealed qualities it can be recommended to patients with AH with high cardiovascular risk.</p>